



## Introduction

Nausea and vomiting (N&V) is a common and troubling complaint in the Emergency Department (ED). There are multiple neural pathways implicated in nausea and vomiting, including serotonin; dopamine; histamine; neurokinin; and cannabinoid receptor pathways. It is with these physiological / chemically mediated changes in mind that we should assess N&V with respect to cause and the pathways implicated prior to prescription decisions.

The aetiology is diverse and treatment is often commenced empirically. The choice of antiemetic should be determined by the clinical situation.

We have identified 12 major causes of N&V in the ED: **Table 1: Adult Antiemetic Guideline**. Always consider the clinical picture (most likely cause), co- morbidities, age & physiological state as well as drug interactions and potential adverse effects prior to prescribing.

## Medication Options

A Cochrane Systematic review found that “In ED populations, there is no definite evidence to support the superiority of any one drug over any other drug, or the superiority of any drug over placebo.” Participants receiving placebo often reported clinically significant improvement in nausea, implying general supportive treatment such as IV fluids, care and reassurance may be sufficient for most people.

There are papers that support the use of smelling isopropyl (alcohol wipe) at triage for antiemetic effect. This highlights the individual experience and response to nausea and its treatments amongst the population.

Please refer to **TABLE 2: Medication Class** for specific information regarding the various recommended medications. This is not a complete list of indications, contraindications, and precautions for each drug. If unsure, please refer to MIMS for complete listings prior to prescribing.

This guideline was developed in response to a shortage of IV Prochlorperazine (April 2023), hence, alternatives should be considered. Please discuss with your Senior for guidance.



# SCGH ED Adult Antiemetic Guideline

TABLE 1: Seek & treat the cause of the nausea and vomiting.

The choice of antiemetic drug is determined by the clinical situation.

Please refer to the entire Guideline for further details and consult a Senior Clinician for guidance.

This Guideline was developed for use within SCGH Adult ED only.

Numbering in the table indicates 1st, 2nd, or 3rd line of therapy.

Medications from the same class should not be given in combination (medication classes are not distinguished on this quick reference table). Check this prior to prescribing. Avoid Dopaminergic agents in Parkinson's Disease and caution <20yrs age.



## MIGRAINE

- 1st - Metoclopramide 10mg PO/IM/IV 8hrly (max 30mg/day)
- 2nd - Prochlorperazine 12.5mg IM/IV-slow 8hrly or 20mg PO single
- 2nd - Domperidone PO 10mg 8hrly (max 30mg/24hrs)
- 2nd - Ondansetron 4 - 8mg 8hrly PO/IV (max 32mg/24hrs)
- 3rd - Chlorpromazine 12.5mg IV (slow infusion over 30min) once only

- Avoid opioid analgesia



## VERTIGO

- 1st - Promethazine 25mg PO 4hrly (max 100mg/24hr) **OR**
- 1st - Prochlorperazine PO 5-10mg 8hrly
- 2nd - Diazepam 5mg PO 8hrly
- 2nd - Ondansetron PO/IV 4 - 8mg 8hrly
- 3rd - Droperidol\* 1mg - 2.5mg IV 6hrly (\*not F1)

- Meniere's Syndrome - Betahistine 8 - 16mg PO TDS
- Consider central causes



## CNS (SAH/SOL)

- 1st - Dexamethasone 4 - 8mg PO/IM/IV 8hrly
- 1st - Ondansetron 4-8mg 8hrly PO/IV (max 32mg/day)
- 2nd - Droperidol\* 0.625mg - 1.25mg IV 8hrly (\*not F1)
- 2nd - Lorazepam\* 0.5mg - 2mg, PO/IV 8-12hrly (\*not F1)

- Consider sedating effects of 2nd line agents in CNS conditions



## GASTROENTERITIS

- 1st - Ondansetron 4mg - 8mg PO/IV 8hrly (max 32mg/24hr)
- 1st - Metoclopramide PO/IM/IV 10mg 8hrly (max 30mg/day) **OR**
- 1st - Prochlorperazine 12.5mg IM/IV-slow 8hrly **OR**
- 1st - Prochlorperazine PO 20mg stat or 5-10mg 8hrly (max 30mg/24hrs)



## BOWEL OBSTRUCTION

- 1st - Ondansetron 4 - 8mg 8hrly PO/IV (max 32mg/day)
- 2nd - Droperidol\* 0.625mg - 1.25mg IV 6hrly (\*not F1)

- Caution Metoclopramide / antiemetics with prokinetic effects - may be prescribed by Senior Clinician in specific circumstances
- Consider NBM & NGT



## CYCLICAL VOMITING

- 1st - Capsaicin 0.075% cream topical to abdomen 12hrly (if due to cannabis)
- 1st - Ondansetron 4-8mg PO/IV 8hrly
- 2nd - Midazolam 0.5mg - 2mg IV with slow titration (may need infusion)
- 2nd - Diazepam\* 2.5 - 5mg IV once (\*not F1)
- 3rd - Droperidol\* 1.25mg IV 6hrly (\*not F1)
- 3rd - Dexamethasone 4-8mg IV stat dose

- Check cannabis use; consider causes & consider PPI



## OPIOID INDUCED

- 1st - Ondansetron 4 - 8mg 8hrly PO/IV (max 32mg/day)
- 1st - Metoclopramide PO/IV 10mg 8hrly (max 30mg/24hrs)
- 2nd - Droperidol\* 0.5mg - 1.25mg IV 6hrly (\*not F1)

- Poor evidence for prophylactic use but consider if vomiting potentially detrimental (eg - spinal precautions etc) Previous Opioid Induced NV (OINV) best predictor for recurrence



## CHEMOTHERAPY

- 1st - Ondansetron PO/IV 4mg - 8mg 8hrly
- 2nd - Olanzapine PO 2.5-5mg 12hrly PRN
- 2nd - Lorazepam 0.5mg - 2mg PO 12hrly
- 2nd - Dexamethasone PO 2 - 8mg 8hrly
- 2nd - Haloperidol PO 0.5mg-2mg 6hrly **OR**
- 2nd - Droperidol\* 0.625 - 1.25mg 8hrly (\*not F1)
- 3rd - Metoclopramide IV 10mg 8hrly

- Liaise with Oncology for alternative treatment if ongoing symptoms



## PALLIATIVE CARE

- Metoclopramide SC 30mg/24hrs\*\*
- Haloperidol SC 1mg-2.5mg/24hrs\*\*
- Promethazine SC 12.5-25 mg/24hrs\*\*
- Olanzapine PO 2.5 - 5mg 12hrly
- Hyoscine PO/SC 20mg 6hrly\*\*
- Lorazepam\* 0.5 - 2mg 6hrly (\*not F1)
- Cyclizine 25 - 50mg IV/SC 8hrly\*\*
- Consider Subcutaneous infusions
- \*\*Liaise with Pall Care Team (dosing may be adjusted under specialist advice)
- Link [WA Palliative Care Guideline](#)



## POSTOPERATIVE NAUSEA & VOMITING

- 1st - Ondansetron 4-8mg 8hrly PO/IV
- 1st - Dexamethasone 4 - 8mg IV daily
- 1st - Droperidol\* 0.5mg - 1.25mg IV 6hrly (\*not F1)
- 2nd - Lorazepam\* 0.5 - 1mg PO/IV 6hrly (\*not F1)
- 2nd - Cyclizine 25 - 50mg IV 8hrly

- Consider medications given intra-operatively



## PREGNANCY

- 1st - Ginger (Cat A) up to 1g daily (not available SCGH, use pts own)
- 1st - Vit B6 / Pyroxidine (Cat A) PO 12.5 - 25mg 8hrly **OR** PO 12.5mg mane & midi & 25mg nocte (\*F1 only for diagnosed Hyperemesis Gravidarum)
- 2nd - Metoclopramide (Cat A) PO/IM/IV 10mg 8hrly
- 3rd - Ondansetron (Cat B1) PO/IV 4 - 8mg 8hrly

- Link [WA KEMH Guidelines](#)

## HYPEREMESIS GRAVIDARUM

- 1st - Metoclopramide (Cat A) PO/IV 10mg 8hrly
- 2nd - Ondansetron (Cat B1) PO/IV 4 - 8mg 8hrly
- 3rd - Prochlorperazine (Cat C) PO 5 - 10mg 6hrly (**OR** 12.5mg IM 8hrly). **OR**
- 3rd - Promethazine (Cat C) PO 10 - 25mg PO 6- 8hrly

- Doxylamine recommended for outpatient therapy
- IV Hydration is key
- Check Ketones
- Link [WA KEMH Guidelines](#)

Dr C Badawy October 2023

\*Not F1 = Use does not meet SCGH Pharmacy Guidelines for this indication / off label prescribing



## SCGH ED Adult Antiemetic Guideline

TABLE 2 : Medication Class - further information on Medications in Table 1.

Anti-cholinergic				
Drug / F1	Pregnancy / BF	MOA / Indications	Side Effects	Dose
<b>Hyoscine Butylbromide</b> F1 unrestricted	Category B2  Pregnancy - safe to use  BF - appears safe	Not used for its antiemetic properties directly, hyoscine is a powerful smooth (antispasmodic) muscle relaxant (through muscarinic receptors) and has some antiemetic properties. Commonly used with other antiemetic agents in Palliative care settings	Contraindicated in paralytic or obstructive ileus myasthenia gravis and glaucoma. May cause drowsiness. Blurred vision, palpitations and dry mouth are rare	<u>Palliative care</u> PO/subcut/IV 20mg 6hrly (120mg/24hrs)  *Refer Pall Care Guidelines/Advice

Anti-histamine				
Drug / F1	Pregnancy / BF	MOA / Indications	Side Effects	Dose
<b>Betahistine</b> F1 unrestricted	Category B2  Pregnancy - limited data  BF - limited data	The exact MOA is unknown. It is believed to be a weak H <sub>1</sub> agonist and stronger H <sub>3</sub> antagonist in CNS & autonomic. It is used in the treatment of Meniere's and vertigo, though not to treat the emetic elements of these conditions, and evidence is very weak.	Multiple medication interactions  Commonly causes headache, nausea, and dyspepsia.	<u>Nausea &amp; Vomiting</u> PO 8mg-16mg 8hrly Maximum of 48mg/24hrs
<b>Cyclizine</b> F1 restricted	Category B3  Pregnancy - safe to use  BF - short term use appears safe (limited data). Main concern is sedation of mother	Potent antihistamine (H <sub>1</sub> receptor) with anticholinergic and antiemetic properties Used for Post-operative nausea & vomiting (PONV), and motion sickness.	Sedation, anticholinergic effects, (caution in patients with underlying glaucoma or those predisposed to urinary retention).	<u>PONV</u> 25mg-50mg IV 8hrly Motion Sickness: 25mg PO 8 – 6hrly  <u>Palliative care</u> Subcut/IV 25-50mg 8hrly (max 200mg/24hrs) *Refer Pall Care Guidelines/Advice
<b>Promethazine</b> F1 tablet unrestricted, injection restricted	Category C  Pregnancy - safe to use  BF - short term use appears safe (limited data). Main concern is sedation of mother	Potent antihistamine (H <sub>1</sub> receptor) and sedative-hypnotic effects, also antiemetic, anti-vertigo, anti-motion sickness, anti-cholinergic effects. Often used for motion sickness	Sedation, and anticholinergic effects. Caution in patients with underlying glaucoma or those predisposed to urinary retention, QT prolongation. Can cause extrapyramidal side effects (dystonic reaction, akathisia, parkinsonism, tardive dyskinesia). Avoid in Parkinson's disease & note multiple drug interactions. May lower seizure threshold. Avoid IV administration	<u>Vertigo</u> PO 25mg 4hrly OR IM 12.5-25mg stat, then Δ to PO  <u>Palliative care</u> PO 12.5mg-25mg 12hrly Continuous subcutaneous infusion (if sufficiently dilute) 25mg/24hrs  Maximum of 100mg/24hrs  *Refer Pall Care Guidelines/Advice

Benzo-diazepines				
Drug / F1	Pregnancy Category	MOA / Indications	Side Effects	Dose
<b>Diazepam</b> F1 restricted	Category C	GABA receptor agonists. Anxiolytic, sedative, muscle relaxant and anti-convulsant effects. Useful in chemotherapy or palliative care related N&V.  Low dose Benzodiazepines useful in cyclical vomiting. PONV and N&V due to opioids.  They are useful anxiolytics, and for short term treatment of insomnia	Sedation, tolerance, dependence and dizziness.  Caution when in combination with drugs that cause CNS and respiratory depression. Consider lower starting dose in elderly and severe renal impairment.  Contraindicated in severe hepatic impairment.	<u>Vertigo (Diazepam)</u> PO 5mg 8hrly
<b>Lorazepam</b> F1 restricted				<u>Cyclical Vomiting (Diazepam)</u> IV 2.5mg-5mg stat
<b>Midazolam</b> F1 unrestricted				<u>CINV (Lorazepam)</u> See treatment protocol OR PO 0.5mg-2mg 12hrly  <u>Cyclical Vomiting (Midazolam)</u> IV 0.5mg-2mg stat (consider low dose infusion)



# SCGH ED Adult Antiemetic Guideline

Corticosteroids				
Drug / F1	Pregnancy / BF	MOA / Indications	Side Effects	Dose
<b>Dexamethasone</b> F1 unrestricted	Category C  Pregnancy - considered safe. Use lowest effective dose for the shortest possible time.  BF - limited data, consider alternate corticosteroid	Synthetic adrenocorticosteroid with glucocorticoid activity, very little mineralocorticoid activity. Anti-inflammatory and immunosuppressant activity. Useful with cytotoxic drugs, PONV, N&V due to bowel obstruction or raised intracranial pressure.	Mood or sleep disturbance, adrenocortical suppression, hyperglycaemia, peptic ulcer Caution in sepsis, haematological malignancies, diabetes, and systemic fungal infections.	<u>Nausea &amp; Vomiting</u> PO/IM/IV 2mg-8mg single dose or up to 8hrly if recurrent vomiting Seek senior advice

Dopamine antagonists				
Drug & F1	Pregnancy / BF	MOA / Indications	Side Effects	Dose
<b>Chlorpromazine</b>  F1 restricted (Intractable migraine)	Category D  Pregnancy - limited data  BF - limited data, small amounts of antipsychotics pass into breast milk	Actions include major tranquiliser, anti-psychotic, dopamine inhibitor, alpha-adrenergic blockade (cause hypotension), may elevate serum glucose.  Indicated for functional psychosis, agitation, depression, behavioural disturbance, palliative care, and intractable hiccough. Widely used as an adjunct in treatment of migraines in ED.	Sedation, hypotension, anticholinergics effects, QT prolongation, extrapyramidal side effects (dystonic reaction, akathisia, parkinsonism, tardive dyskinesia). Avoid in Parkinson's Disease May lower seizure threshold. Avoid in Pregnancy	<u>Migraine</u> IV 12.5 mg in NaCl 0.9% 1Lt over 30 minutes. If needed, repeat infusion once, 30 minutes after preceding infusion ends Maximum of 37.5mg/24hrs  To avoid hypotension, pre-treat with NaCl 0.9% 500mL. Monitor blood pressure and fluid status every 30 minutes during treatment
<b>Droperidol</b>  F1 restricted (2 <sup>nd</sup> line therapy PONV)	<b>Category C</b>  <b>Pregnancy - limited data</b> <b>Breast Feeding (BF) - limited data suggests small amounts of antipsychotics pass into breast milk.</b>	Dopamine antagonist, with antipsychotic & antiemetic properties. Use for N&V refractory to other antiemetics, opioid induced, anxious, or agitated patients, produces sedation in higher doses.	Sedation (especially with higher doses), QT prolongation, extrapyramidal side effects (dystonic reaction, akathisia, parkinsonism, tardive dyskinesia) Avoid in Parkinson's Disease. May reduce seizure threshold.	<u>PONV</u> IV 0.25mg – 1.25mg for nausea, up to 2.5mg IV 8hrly PRN for vertigo.
<b>Metoclopramide</b>  F1 unrestricted	<b>Category A</b>  Pregnancy - safe to use  BF - safe to use s	Metoclopramide has gastric pro-kinetic effects and dopamine antagonist activity  Use for migraine (in combination with paracetamol), acute gastroenteritis. Considered the safest antiemetic in pregnancy, may be useful in diabetic gastroparesis.	Can cause extrapyramidal side effects (dystonic reaction, akathisia, parkinsonism, tardive dyskinesia). Avoid in Parkinson's Disease & young patients <20yrs Avoid in bowel obstruction or perforation/resection due to its pro-kinetic activity. Short term use only (5 days) risk of tardive dyskinesia increases with cumulative dose and length of treatment	<u>All Indications</u> PO/IM/IV 10mg 8hrly  Maximum daily dose should not exceed 0.5 mg/kg or 30 mg (whichever is less)  <u>Palliative care</u> Continuous subcutaneous infusion 30mg/24hrs *Refer Pall Care Guidelines/Advice – dosage may be altered by Senior Clinician.
<b>Prochlorperazine</b>  F1 unrestricted	Category C  Pregnancy - safe to use in early pregnancy. In late pregnancy there is a risk of neurological disturbance in infant  BF - safe to use	Acts on several neurotransmitter systems, anti-dopamine, alpha-adrenoreceptor antagonism, potentiation of noradrenaline, weak anticholinergic action, weak antihistamine action, weak serotonin antagonism.  Use for N&V due to migraine, vertigo due to Meniere's, motion sickness, labyrinthitis or acute gastroenteritis (2 <sup>nd</sup> line).	Sedation, long QT, extrapyramidal side effects (dystonic reaction, akathisia, parkinsonism, tardive dyskinesia). Avoid in Parkinson's Disease May lower seizure threshold. May cause constipation, blurred vision and hypotension.	<u>Vertigo</u> PO 5-10mg 6-8hrly <b>OR</b> IM 12.5mg stat, then Δ to PO (Treat for ≤2 days) <u>Migraine</u> PO 20mg stat followed by 10mg 2 hours later <b>OR</b> 5mg-10mg 8hrly <u>Gastroenteritis</u> PO 20mg stat <b>OR</b> 5-10mg 6-8hrly IM/IV(slow) 12.5mg 8hrly <u>Pregnancy</u> <b>PO 5mg-10mg 6-8hrly <b>OR</b></b> <b>IM/IV(slow) 12.5mg 8hrly</b>



# SCGH ED Adult Antiemetic Guideline

Dopamine antagonists				
Drug / F1	Pregnancy / BF	MOA / Indications	Side Effects	Dose
<b>Domperidone</b>  F1 unrestricted	Category B2  Pregnancy - avoid use  BF - safe to use	Antiemetic due to pro-kinesis and central dopamine antagonism in the chemo-receptor trigger zone (CTZ). Indicated for short term treatment of gastroparesis (idiopathic or diabetic) and for intractable N&V from any cause. Commonly prescribed for Oncology patients. Antiemetic properties similar to metoclopramide; however, it does not readily cross the blood brain barrier. Rarely causes extra-pyramidal side effects but does increase prolactin levels.	Dry mouth, headache, hyperprolactinaemia, rash, insomnia, prolonged QT interval. Avoid in prolactinoma Contraindicated in mod-severe hepatic impairment Caution with other CYP3A4 inhibitors.  Short term use for nausea and vomiting (≤7 days)	<u>Nausea &amp; Vomiting</u> PO 10mg 8hrly  Maximum of 30mg/24hrs.

Atypical Anti-Psychotic				
Drug / F1	Pregnancy / BF	MOA / Indications	Side Effects	Dose
<b>Olanzapine</b> F1 restricted (Chemotherapy Induced Vomiting (CINV) and palliative care)	Category C  Pregnancy - limited data  BF - limited data, small amounts of antipsychotics pass into breast milk	Atypical antipsychotic, antimanic, mood stabilising agent with a broad profile. Affinities for dopamine, cholinergic muscarinic, alpha1 Adrenergic and antihistamine receptors. Used for Palliative Care and in N&V due to Chemotherapy.	Sedation, hypotension, anticholinergic effects (caution in patients with underlying glaucoma or those predisposed to urinary retention), QT prolongation, extrapyramidal side effects (dystonic reaction, akathisia, parkinsonism, tardive dyskinesia). Avoid in Parkinson's Disease May lower seizure threshold	<u>Palliative care</u> PO/subling 2.5mg-5mg 12hrly *Refer Pall Care Guidelines/Advice  <u>Chemotherapy</u> See treatment protocol OR PO/subling 5-10mg 12hrly  <u>Elderly, renal or hepatic impairment start</u> PO 2.5mg-5mg once daily

5-HT <sub>3</sub> receptor antagonists				
Drug / F1	Pregnancy / BF	MOA / Indications	Side Effects	Dose
<b>Ondansetron</b> F1 unrestricted	Category B1  Pregnancy - may be used for nausea and vomiting if other drugs are inadequate (3rd line)  BF - No data available, although 1 or 2 doses after delivery should not be a concern	5-HT <sub>3</sub> receptor-antagonist. Antagonises presynaptic 5-HT <sub>3</sub> receptors at peripheral receptors in the GIT and, to a lesser extent, the CNS.  Official (PBS) indications are for emetogenic chemotherapy, radiotherapy and PONV, although it is widely used in many other circumstances.	Headache is common, constipation, QT prolongation (caution if coexistent hypokalaemia, hypomagnesaemia or hypocalcaemia, risk of serotonin toxicity in combination with other serotonergic agents.	<u>All Indications</u> PO/IV 4mg-8mg 8hrly  Maximum of 20mg/24hrs (Consider reducing maximum dose if patient >75years)  Do not exceed 8mg/24hrs in severe hepatic impairment

Other				
Drug / F1	Pregnancy Category	MOA / Indications	Side Effects	Dose
<b>Capsaicin 0.075% Cream</b> F1 unrestricted	Data not available	Acts via sensory nerve blockade through substance P depletion. Used topically for arthritis pain or post herpetic neuralgia. Off label use for cannabis hyperemesis syndrome (has limited evidence)	Avoid in broken skin, oral, ocular or other sensitive mucosa.	<u>Cannabis hyperemesis syndrome</u> TOPICAL - Apply to the abdomen 12hrly
<b>Clonidine</b> F1 unrestricted	Category B3	Central alpha <sub>2</sub> agonist. At low doses, clonidine is can reduce nausea. It is also commonly used for post operative pain and to reduce opioid consumption.	Caution in bradycardias, sick sinus or high AV block. May cause sedation and variable effects of hypotension. Dizziness is common	<u>Cyclical Vomiting</u> IV 15microg – 60microg stat



## References

1. ETG “Antiemetic Drugs in Adults” (Accessed April 2023)
2. ETG “Oral antiemetics for nausea and vomiting during pregnancy” (Accessed April 2023)
3. ETG “Drug and Radiation-induced nausea and vomiting in adults” (Accessed April 2023)
4. ETG “Postoperative nausea and vomiting in adults” (Accessed April 2023)
5. Australian Prescriber “Antiemetic Drugs: what to prescribe & when” Vol 43:2 2020
6. AMH “Nausea & Vomiting” (Accessed April 2023)
7. BMJ Best Practice “Assessment of nausea and vomiting, adults” Jul 15, 2022
8. Up to Date “Approach to the Adult with Nausea & Vomiting” May31, 2022
9. Cochrane Library “Drugs for the treatment of nausea & vomiting in adults in the Emergency Department setting (Review)” Furyk JS, Meek RA, Egerton-Warburton D. 2015, Issue 9.
10. MIMS Online (Accessed April – August 2023)
11. Emergency Medicine Manual, Dunn et al ( Accessed April 2023)
12. International Journal of Emergency Medicine “Implementation of Isopropyl alcohol inhalation (IPA) as the first-line treatment for nausea in the emergency department: practical advantages and influence on the quality of care” Veldhuis et al, 2021, Feb 14(1)
13. Australian Family Physician “Palliating Symptoms Other than Pain” Dr Jane Fischer, Vol 35, 10 Oct 2006.
14. The Toxicology Handbook, Dr Jason Armstrong & Dr Ovidiu Pascu, 4<sup>th</sup> Ed, 2022
15. Austin Clinical Toxicology Guidelines “Cannabinoid Hyperemesis Syndrome” (Accessed April 2023)
16. Cancer Institute NSW, Clinical Resources, Side Effects & Toxicity Management (Accessed October 2023)  
<https://www.eviq.org.au/clinical-resources/side-effect-and-toxicity-management/gastrointestinal>
17. LINK – KEMH Nausea and Vomiting in Pregnancy -  
<https://www.kemh.health.wa.gov.au/~media/HSPs/NMHS/Hospitals/WNHS/Documents/Patients-resources/Nausea-and-vomiting-in-pregnancy.pdf>
18. LINK – WA Health Palliative Care Guideline  
[https://ww2.health.wa.gov.au/~media/Files/Corporate/general%20documents/Palliative/Evidence\\_based\\_guidelines.pdf](https://ww2.health.wa.gov.au/~media/Files/Corporate/general%20documents/Palliative/Evidence_based_guidelines.pdf)

Created	August 2023
Next Review date	August 2025
Review panel.	SCGH Emergency Medicine & Pharmacy - Created by Dr Chantelle Badawy; Review by Dr Tony Celenza; Monique Cook (Senior Pharmacist); Dr Katherine Jutsum; Dr Ioana Vlad, Dr Anil Tandon (Palliative Care)

This guideline was written exclusively for adult patients for use by SCGH ED staff only.  
The authors do not support its use outside of the department.  
We recommend that practitioners refer to local departmental guidelines.